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Polymorphism of the TNF-a, HSP70-2, and CD14 Genes
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Tamas Taka´cs, MD, PhD,§ Janos Lonovics, MD, PhD,§ and Yvette Ma´ndi, MD, PhD*
Objectives: Proinﬂammatory cytokines and heat shock proteins
play fundamental roles in the pathogenesis of acute pancreatitis. We
studied whether polymorphisms of the tumor necrosis factor a (TNF-a),
heat shock protein 70-2 (HSP70-2), and CD14 genes correlate with
the severity of acute pancreatitis.
Methods: Patients with acute pancreatitis (n = 77) of mixed etiology
were grouped according to the severity of the disease on the basis of
the Ranson scores. Healthy blood donors (n = 71) served as controls.
TNF-a-308 polymorphism was determined by NcoI RFLP, HSP70-2
polymorphism by PstI RFLP, and CD14-159 polymorphism by
melting point analysis.
Results: There was a moderate increase in the frequency of the
TNF1/2 genotype (P = 0.046) among patients with severe acute
pancreatitis as compared with those with mild disease. A more
signiﬁcant increase was observed in the frequency of the HSP70-2 G
allele between groups of patients with mild or severe pancreatitis
(18.9% vs. 53%; P , 0.001). Conversely, the A/A genotype was
markedly more frequent among the patients with mild pancreatitis
(P, 0.0001). There was no signiﬁcant correlation between CD14-159
promoter polymorphism and the severity of pancreatitis.
Conclusion: High frequencies of the HSP70-2 G and the TNF-a -
308 A alleles were associated with risk of severe acute pancreatitis.
Genotype assessments may be important prognostic tools to predict
disease severity and the course of acute pancreatitis. Therefore,
genotype assessments may also be used to guide treatment or to
identify risk populations for severe acute pancreatitis.
KeyWords: gene polymorphism, tumor necrosis factor a, heat shock
protein 70-2, CD14, acute pancreatitis, disease severity
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The importance of proinﬂammatory cytokines in thepathogenesis of acute pancreatitis is well established.1–3
For example, tumor necrosis factor a (TNF-a) plays an
important role in the early activation of the cytokine cascade,
which leads to the production of other proinﬂammatory
cytokines, such as interleukin-6 and -8.4 Although the clinical
course of acute pancreatitis is often mild with only minimal
organ dysfunction, a signiﬁcant portion of the patients with
acute pancreatitis develops severe disease often associated
with local inﬂammation, multiple organ failure, and infec-
tions.5 As TNF-a production is determined partially by genetic
factors,6,7 we hypothesized that polymorphism of the TNF
gene may inﬂuence disease susceptibility and the severity of
acute pancreatitis.
TNF-a production and response are regulated at the
transcription level; therefore, the role of polymorphisms of the
TNF promoter in the determination of inﬂammatory disease
susceptibility, or as a marker of disease severity, has been
a subject of intensive research.7,8 The TNF-a gene exhibits
polymorphism at position -308 in the promoter region, with
either G in the TNF1 allele or A in the TNF2 allele.6 The TNF2
allele is associated with increased transcription and a high
level of TNF-a in blood.9
There is increasing evidence that the induction of heat
shock proteins (HSPs) may have a protective effect in
experimental pancreatitis.10,11 For instance, Fossard et al12
have reported the protective effect of HSP70-2 against cerulein-
induced pancreatitis, which occurred via limited intrapancre-
atic digestive enzyme activation under both thermal and
nonthermal stresses. Stress-induced HSP70-2 expression pre-
vented the activation of intracellular trypsinogen by cerulein in
freshly isolated segments of rat pancreas.11
In humans, 3 members of the HSP70 gene family have
been mapped and described. They include HSP70-1, HSP70-2,
and HSP70-HOM, of which HSP70-2 encodes the major heat-
inducible HSP70. This gene has been shown to be poly-
morphic by Milner et al,13 who identiﬁed the polymorphic A to
G transition PstI site at position 1267 in the coding region of
HSP70-2. Individuals homozygous for the HSP70-2 G allele
display a decrease in inducible HSP70-2 mRNA expression.14
Recent studies indicate that HSP70-2 A(1267)G poly-
morphism is associated with increased risks and poor
outcomes of several diseases,15–18 but acute pancreatitis has
not been investigated in this respect. As susceptibility to
multiple organ damage may depend on the ability of the
organism to express HSPs, we therefore investigated whether
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genetic variations in HSP70-2 are prognostic for the clinical
outcome of acute pancreatitis.
We also sought a correlation between promoter gene
polymorphisms of the LPS receptor CD14 and the severity of
acute pancreatitis. CD14 also initiates the cytokine cascade by
acting as a pattern recognition receptor.19 CD14 exhibit bind-
ing speciﬁcity for molecules that allow CD14 to initiate innate
immune responses. Furthermore, human CD14 mediates the
recognition and phagocytosis of ‘‘self’’ components, such as
apoptotic cells.20 Polymorphism at position -159 in the
promoter region of the CD14 gene has been shown to affect
the expression of CD14, where the T allele is associated with
a high expression of CD14 on circulating monocytes.21
PATIENTS AND METHODS
Patient Groups
We herein report a prospective study involving 77 pa-
tients with acute pancreatitis and their genetic polymorphism.
The criteria for diagnosis of acute pancreatitis were the clinical
history consistent with the disease, radiologic evidence, and
a serum amylase level greater than 660 U/L. Patients entered
this prospective study at the Department of Surgery and the
Department of Internal Medicine of Albert Szent-Gyo¨rgyi
Medical Center of Szeged University from March 2003 to
February 2004. This study was approved by the Institutional
Review Board of the Faculty of Medicine. All patients were
classiﬁed as having mild or severe pancreatitis according to the
original criteria of Ranson22: mild pancreatitis, patients with
fewer than 3 positive prognostic signs (n = 29) and severe
pancreatitis, patients with 3 or more positive prognostic signs
(n = 48). Patients with severe acute necrotizing pancreatitis
were divided into aseptic (n = 28) or infected (n = 20) groups
based on bacterial cultures of the necrotic pancreatic tissue
sampled during surgery or US- or CT-guided biopsies (Table 1).
In 34 patients acute pancreatitis was caused by alcohol
(.80g/d), in 25 patients the cause was cholelithiasis, and in 8
patients, no cause could be identiﬁed (idiopathic) (Table 1).
During hospitalization, laboratory parameters including
sedimentation rate, leukocyte count, hematocrit, Na, K, Ca, P,
urea, base excess, amylase, glucose, bilirubin, alkaline phos-
phatase, CRP, and procalcitonin (PCT) were determined. All
patients underwent chest x-ray, abdominal x-ray, US and
contrast enhanced abdominal CT examinations repeatedly.
Endoscopic retrograde cholangiopancreatography (ERCP)
was performed when biliary pancreatitis was suspected. In
patients with biliary tract lithiasis, stone extraction was carried
out by endoscopic sphincterotomy.
Healthy Subjects
The control cohort consisted of a random, unrelated
population sample involving 71 healthy blood donors. All
cases and controls were of Hungarian ethnic origin and resided
in Hungary. All patients consented to the study and were
treated according to the Patient Right Protection Act of our
institution as well as international guidelines.
DNA Isolation
For the examination of TNF-a, HSP70-2, and CD14
polymorphisms, genomic DNA puriﬁed from peripheral blood
was used. Leukocyte DNA was isolated using the High Pure
PCRTemplate Preparation Kit according to the manufacturer’s
instructions (Roche Diagnostic GmbH, Mannheim, Germany)
and the genomic DNAwas stored at 220C until further use.
Determination of TNF-a -308 Polymorphism
The G!A transition at position -308 in the promoter
region deﬁnes the rare allele 2 associated with an elevated
expression of this cytokine.9 A single base change at the 3#
end of primer A1 (underlined) was required for the for-
mation of an NcoI recognition sequence.6 PCR primers:
A1: 5# AGGCAATAGGTTTTGAGGGCCAT 3#; A2: 5#
TCCTCCCTGCTCCGATTCCG 3#. One hundred nanograms
of genomic DNA was ampliﬁed using Taq DNA polymerase
(Fermentas, Vilnius, Lithuania) with 1.5 mol/L MgCl2, under
the following conditions: 94C for 3 minutes followed by 36
cycles of 94C for 1 minute, 60C for 1 minute, and 72C for 1
minute, with an extension of 72C for 5 minutes. The
ampliﬁed product was digested with NcoI (Fermentas) and
analyzed on a 12% polyacrylamide gel. Digestion conﬁrmed 2
alleles. Allele 1 gives 2 fragments of 87 and 20 bp and allele 2
a single 107-bp fragment.
Determination of HSP70-2 1267
A!G Polymorphism
HSP70-2 RFLP was assessed by means of a polymerase
chain reaction procedure using the following primers (sense:
5#-TCCGAAGGACTGAGCTCTTG-3# and antisense:
5#-CAGCAAAGTCCTTGAGTCCC-3#) spanning the poly-
morphic PstI site (nucleotide 1267). The PCR reaction mixture
(50 mL) contained 50–150 ng DNA, 25 pmol of primers, 1.25
U Taq polymerase (Fermentas), 103 PCR buffer with
(NH4)2SO4, 1.5 mmol/L MgCl2, 0.2 mmol/L of each dNTP
(Fermantas). The PCR procedures started on 95C for 3
minutes, then 35 cycles of denaturing at 95C for 20 seconds,
annealing at 60C for 20 seconds, extension at 72C 90
seconds, and ﬁnally 6 minutes at 72C. For RFLP analysis, the
PCR products were digested by PstI (Fermantas) at 37C
overnight and electrophoresed on a 1.5% agarose gel (Sigma-
Aldrich, St. Louis, MO), visualized under UV illumination and
stained with 0.4 mg/L ethidium bromide. The presence of
TABLE 1. Characteristics of Patients With Acute Pancreatitis
Mild*
Severe†
SPN IPN
No. of patients 29 28 20
Age (yr) (range) 57.79 (27–93) 59.53 (30–81) 44.42 (21–79)
Sex (M/F) 12/17 13/15 15/5
Etiology
Biliary 18 14 4
Alcoholic 9 13 12
Idiopathic 2 2 4
*Ranson score ,3.
†Ranson score .3.
SPN, sterile pancreatic necrosis,
IPN, infected pancreatic necrosis.
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a PstI site (G allele) was indicated by cleavage of the 2075 bp
ampliﬁed PCR product to yield 1159 and 916 bp fragments.
CD14 -159 C!T Gene Polymorphism
Genotyping for CD14 -159 C!T polymorphism was
based on a real-time polymerase chain reaction (RT PCR)
assay using speciﬁc ﬂuorescence-labeled hybridization
probes and melting point analysis. The 10-mL RT PCR
mixture contained 1 mL (20–80 ng) genomic DNA, 0.2 mL
MgCl2 (25 mmol/L), 1 mL reaction buffer (LightCycler DNA
Master Hybridization Probes 103 buffer, Roche Diagnostics
GmbH, Mannheim, Germany), 0.5 mmol/L of the primers
(sense: 5#-GGTGCCAACAGATGAGGTTCAC, antisense:
5#-CTTCGGCT-GCCTCTGACAGTT) as well as 0.2 mmol/L
of the detection probe speciﬁc for the T allele (5#-LC Red
640-TTCCTGTTACGGCCCCCCT-p, the 3# end was phos-
phorylated to block extension), and the anchor probe (5#-
GGAGACACAGAACCCTAGATGCCCTGCA-ﬂuorescein)
(ref. no. 003108781; TIB Molbiol, Berlin, Germany) were
used. The RT PCR conditions were initial denaturation at 95C
for 120 seconds, followed by 60 cycles of denaturation (95C
for 0 seconds, 20C/s), annealing (55C for 10 seconds) and
extension (72C for 10 seconds). The melting curve consisted
of 1 cycle at 95C for 45 seconds and at 45C for 150 seconds,
increasing the temperature to 95C at a slope of 0.1C/s. The
thermocycler was a LightCycler instrument (Roche Diagnos-
tics). Based on the derivative melting curves [2(dF/dT) versus T],
a sample was classiﬁed as genotype TT, CT, or CC.
Statistical Analysis
The level of signiﬁcance in the genotype and allele
frequency was analyzed using the Fisher exact test or x2 test
when appropriate. The probability level of P , 0.05 indicated
statistical signiﬁcance. The relationship between the genotypes
or carriage of individual alleles and disease severity is
presented as the odds ratio (OR), with a 95% conﬁdence
interval (CI) of odds ratio (95% CI). All statistical calculations
were performed with the GraphPad Prism 4 statistical program
(GraphPad Software, Inc., San Diego, CA). The genotype
frequencies for each polymorphism were tested for deviation
from the Hardy-Weinberg equilibrium by the x2-test, with
1 degree of freedom used.
RESULTS
The distributions of genotypes and alleles for the
different polymorphisms were consistent with those predicted
by the Hardy-Weinberg equilibrium in the patients and in the
controls.
TNF-a -308 Polymorphism
The frequency distribution of genotypes for TNF-a gene
polymorphism is shown in Table 2. Overall, there was no
signiﬁcant difference in the distribution of the TNF -308
genotype between the patients with acute pancreatitis and the
healthy controls. However, when the patients were stratiﬁed
according to disease severity, there was a higher frequency of
the TNF1/2 genotype among patients with the severe disease
as compared with the patients with mild pancreatitis (19 of 48
patients versus 5 of 29 patients, P = 0.046; OR, 3.145; 95%
CI = 1.022–9.678). Carriage of the high secreting allele (TNF2)
was signiﬁcantly different between the 2 groups (P = 0.018;
OR, 3.340; 95% CI = 1.192–9.355), although the number of
homozygotes itself was very low. Likewise, the frequency of
the TNF 1/1 genotype was signiﬁcantly higher in the patients
with mild disease as compared with patients with the severe
form of pancreatitis (24 of 29 patients versus 27 of 48 patients;
P = 0.024; OR, 3.733; 95% CI = 1.218–11.44).
HSP70-2 Polymorphism
The frequencies of the HSP70-2 genotypes are shown in
Table 3. The genotypic frequencies were signiﬁcantly different
between severe and mild pancreatitis. This was due to
overexpression of the HSP70-2 G allele in the severe
population (53.1%). The frequency of AG genotype was also
signiﬁcantly higher in the severe group (31 of 48 patients
versus 7 of 29 patients, P = 0.009; OR, 5.731; 95% CI =
2.033–16.15). No signiﬁcant difference was found, however,
in the frequency of either the A or G allele between the
pancreatitis patients overall and healthy controls. This
connotes that the HSP70-2 alleles are not directly implicated
in disease predisposition; however, patients carrying the G
allele might be at higher risk of the severe form of acute
pancreatitis. Alternatively, the ‘‘protective’’ AA genotype is
markedly more frequent among the patients who have only
a mild form of pancreatitis (20 of 29 patients versus 7 of 48
patients, P, 0.0001; OR, 13.02, 95% CI = 4.232–40.03). The
frequency of the AA genotype was signiﬁcantly higher in
patients with mild disease than in the severe form of acute
pancreatitis or even in healthy donors (x2 = 23.84, Fig. 1).
CD14-159 Polymorphism
We did not ﬁnd a correlation between CD14-159
promoter polymorphism and any forms of the acute
pancreatitis investigated herein. Furthermore, there were no
TABLE 2. TNF-a-308 Genotypes and TNF2 Allele
Frequencies (%) in Patients With Acute Pancreatitis and
Controls
1/1 1/2 2/2 2%
Mild (n = 29) 24/29 5/29 0/29 8.6 (5/58)
Severe (n = 48) 27/48 19/48 2/48 23.9 (23/96)
P = 0.024 P = 0.0462 P = 0.018
Total (N = 77) 51/77 24/77 2/77 18.1 (28/154)
Control (N = 71) 51/71 18/71 2/71 15.4 (22/142)
ns vs. total ns vs. total ns vs. total
TABLE 3. HSP70-2 Genotype and G Allele Frequencies
(%) in Patients With Acute Pancreatitis and Controls
AA AG GG G%
Mild (n = 29) 20/29 7/29 2/29 18.9 (11/58)
Severe (n = 48) 7/48 31/48 10/48 53.1 (51/96)
P , 0.0001 P = 0.0009 P , 0.0001
Total (N = 77) 27/77 38/77 12/77 40.2 (62/154)
Control (N = 71) 32/71 30/71 9/71 35.9 (51/142)
ns vs. total ns vs. total ns vs. total
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signiﬁcant differences in CD14-159 genotype frequencies
between patients and the healthy control group (Table 4).
DISCUSSION
The results of this study raise new questions about the
clinical relevance of speciﬁc heat shock proteins, particularly
their expression and polymorphism, in acute pancreatitis. This
is owing to the fact that genetic variations in HSP70-2, as the
major discovery of this report, may be of clinical importance
when it concerns the severity of the disease. Developmental
studies suggest that heat shock proteins play an important role
in pancreatitis.10,11,23–26 Although previous studies clearly
demonstrate the importance of HSP70-2 polymorphism in an
increased risk of hypoxia-related diseases,27 data have not
been reported in connection with acute pancreatitis. We are the
ﬁrst to demonstrate this association between low HSP72 G
allele frequency and severe acute pancreatitis. Our study
revealed that the HSP70-2 G allele, which has been associated
with a low HSP70-2 expression, is more prevalent in severe
pancreatitis than in mild disease or in the healthy population.
Conversely, patients with the ‘‘protective’’ AA genotype are
less vulnerable to severe disease and expected to have a better
prognosis by surviving pancreatitis with far fewer complica-
tions.
Systemic inﬂammation triggered by acute pancreatitis
involves multiple pathways and evidently cannot be explained
by the action of a single mediator. Oxidative stress and cyto-
kines appear to be of particular importance. The close rela-
tionship of antioxidant enzyme gene polymorphisms with the
severity of acute pancreatitis has recently been reported.28
Previous studies of proinﬂammatory cytokine gene
variations have failed to reveal their disease predicting role and
close relationship with the development of a severe attack of
acute pancreatitis29–31; however, our results suggest that the
carrying of the TNF2 allele may be a signiﬁcant factor in the
process. There are many reasons for considering that TNF-a is
involved in the pathogenesis of severe acute pancreatitis, as it
mediates many symptoms such as fever, hypotension, shock,
and multiple organ dysfunction, all of which are present during
a severe attack.1,4 High TNF-a producer genotypes proved to
be more frequent among the patients with severe pancreatitis.
The difference was signiﬁcant only when the 2 groups of
patients were compared; a signiﬁcant difference was not
observed between the patients and healthy donors. Again, this
draws attention to the fact that carrying of the TNF2 allele
itself is not a factor predisposing to acute pancreatitis, but once
it has developed, the higher TNF-a–producing genotype
exacerbates inﬂammatory processes with more severe con-
sequences of the disease. Our results on TNF-a and HSP70-2
gene polymorphisms allow the speculation that the constel-
lation of a high TNF-a producer and the low HSP70-2
producer genetic variant increases the risk of developing
severe acute pancreatitis. It is noteworthy that the coexistence
of TNF2 and HSP70-2 G was detected in 9 of the 49 patients in
the severe group, and 6 of these patients suffered from infected
pancreatic necrosis (6 of the 20 patients with infected necrosis)
with multiple organ failure; 1 of them died. This coexistence
was observed only in 1 case among the patients with mild
pancreatitis (1 of 29). Accordingly, we presume that individ-
uals demonstrating the simultaneous presence of these poly-
morphisms (with 2 ‘‘high-risk’’ genotypes) may be predisposed
to the most severe complications of acute necrotizing
pancreatitis. However, the relatively small size of the subgroup
cohorts warrants further investigations. Hence, we only suggest
that a single carrier state of either TNF2 or HSP70-2 G might
be a risk factor of severe disease and further studies will be
necessary using larger cohorts to further validate our ﬁndings.
We found no correlation among CD14 promoter gene
polymorphism, disease severity, and susceptibility to acute
pancreatitis. The activation of CD14 by LPS or by other
bacterial products could still be extremely important in cases
of pancreatic necrosis associated with infection. Although we
did not ﬁnd signiﬁcant differences in CD14 polymorphism
associated with infected or aseptic pancreatic necrosis (data
not shown), the low number of cases examined and reported to
date warrants further investigations among cases of infected
pancreatic necrosis to ﬁnd a meaningful correlation if it exists.
In summary, our results indicate that the risk of severe
acute pancreatitis is increased in patients carrying the TNF2
allele at the -308 promoter site of TNF-a, and the G allele of
HSP70-2. The HSP70-2 G allele is also more prevalent in
severe pancreatitis cases than in healthy controls. The AA
genotype of the HSP70-2 gene is associated with a less severe
form of acute pancreatitis. Besides the role of the initiation of
the cytokine cascade, these results provide evidence of the
FIGURE 1. The allelic frequencies of the HSP70-2 1267 A!G
polymorphism in the different patient groups were assessed
with RFLP using a PstI cleavage site. Bars indicate the
percentage of patients carrying the AA (wild type, ‘‘pro-
tective’’) alleles. Genotypic frequencies were compared by
x2 test. Statistical signiﬁcance was taken at the P = 0.05 level.
TABLE 4. CD14-159 Genotypes and T Allele
Frequencies (%) With Acute Pancreatitis
CC CT TT T %
Mild (n = 29) 9/29 15/29 5/29 43.10 (25/58)
Severe (n = 48) 13/48 20/48 15/48 52.08 (50/96)
Control (N = 71) 21/71 39/71 11/71 49.95 (61/142)
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importance of heat shock proteins in the pathomechanism of
acute pancreatitis, thereby suggesting the clinical value of
genotype assessment as an important predictive tool associated
with disease severity. Genotype assessments therefore may pro-
vide important clinical evaluation criteria to guide treatment or
to identify risk populations for severe acute pancreatitis.
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